LINE in the 13F filings
Lineage Cell Theraputics In · CUSIP 53566V106
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 14 Feb 2025
- latest of these filings; the earliest 31 Jan 2025
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 9 listed it in both
- Shares listed
- 18,518,457
- combined, among listed positions
- Reported value
- $1.1bn
- combined, at the quarter end
Among the 94 comparable managers: 9 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing LINE in Q4 2024
12 of 12 holders
Largest increases and reductions, by shares
Increases
- D1 Capital Partners LPexisting position · 3,753,598 shares now+2,703,598
- Janus Henderson Group Ltdexisting position · 3,233,219 shares now+1,550,478
- Baillie Gifford & Coexisting position · 3,098,580 shares now+1,384,481
- Capital Research Global Investorsexisting position · 2,000,433 shares now+1,000,433
- Capital World Investorsexisting position · 3,064,842 shares now+563,078
Reductions
- T. Rowe Price Associates Incexisting position · 2,484,110 shares now-2,215,744
- Holocene Advisors LPexisting position · 69,081 shares now-147,329
New positions and exits
New (0)
No new position among listed positions.
Exited (5)
- Wellington Management Group LLPwas $266m
- Hudson Bay Capital Management LPwas $35m
- Altimeter Capital Management LPwas $31m
- Maverick Capital Ltdwas $27m
- Soros Fund Management LLCwas $20m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2024 | 16 | $1.5bn | 16 | 0 |
| Q4 2024 | 12 | $1.1bn | 9 | 7 |
| Q1 2025 | 9 | $1.3bn | 6 | 3 |
| Q2 2025 | 11 | $1.0bn | 8 | 3 |
| Q3 2025 | 7 | $646m | 4 | 4 |
| Q4 2025 | 6 | $481m | 13 | 12 |
| Q1 2026 | 4 | $341m | 13 | 12 |
| Q2 2026 | 4 | $513m | 9 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LINE and WELL →LINE and EQIX →LINE and PLD →Choose a stock to compare with LINE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LINE, latest filings →Back to the 13F Explorer →